The codeine to morphine concentration ratio is used in forensic toxicology to assess if codeine has been ingested alone or if morphine and/or heroin have been ingested in addition. In our experience, this interpretation is more difficult in autopsy cases compared with samples from living persons, since high morphine concentrations are observed in cases where only codeine is assumed to have been ingested. We have investigated if codeine and morphine glucuronides are subject to cleavage to the same extent in living and autopsy cases in vitro. We included whole blood samples from eight living subjects and nine forensic autopsy cases, where only codeine ingestion was suspected. All samples were incubated for 2 weeks at 378 8 8 8 8C and analyzed for codeine and six codeine metabolites using liquid chromatography tandem mass spectrometry. A reduction in the codeine to morphine concentration ratio was found, both in samples from living subjects (mean 33%, range 22 -50%) and autopsy cases (mean 37%, range 13 -54%). The increase in the morphine concentrations was greater in the autopsy cases (mean 85%, max 200%) compared with that of the living cases (mean 51%, max 87%). No changes were seen for codeine or codeine-6-glucuronide concentrations. The altered ratios might mislead the forensic toxicologist to suspect morphine or heroin consumption in cases where only codeine has been ingested.
Introduction
Codeine is an opiate analgesic, predominantly prescribed for the treatment of moderate pain or as an antitussive agent. In Norway, codeine is mainly used as an analgesic in combination with paracetamol (acetaminophen) (1) . In other countries, codeine is also available in different combinations, e.g., with acetylsalicylic acid, ibuprofen, carisoprodol, caffeine, barbiturates or sedative antihistamines.
The analgesic property of codeine is considered to be due to the O-demethylation of codeine into morphine by cytochrome P450 2D6 (CYP2D6), occurring mainly in the liver (2). Lo¨tsch et al. have shown an overview of the metabolism of codeine into the different metabolites (3), see Figure 1 for an overview of the codeine metabolites. Due to genetic polymorphism on the CYP2D6 gene, the amount of morphine produced from codeine varies, with somewhere between 0 and 15% of codeine being metabolized into morphine in the body. The lack of functional CYP2D6 enzyme activity ('poor metabolizers') has been reported for 7-10% of Caucasians, thereby being completely unable or only able to convert a small amount of codeine into morphine. However, another 1-3% of Caucasians have been shown to possess an allele duplication on the gene encoding CYP2D6 ('ultrarapid metabolizers') (4), and are therefore able to metabolize a larger proportion of ingested codeine into morphine (5) .
About 90% of the morphine produced from codeine, in the body, is further metabolized, mainly into morphine-3-glucuronide (M3G) (45-55%) and morphine-6-glucuronide (M6G) (10-15%) (6) . A minor proportion of morphine is N-demethylated into normorphine (5) .
Codeine-6-glucuronide (C6G) is the major codeine metabolite (constituting 50-70% of all the metabolites) (7) . Due to reports of analgesic activity by codeine in subjects without morphineformation, it has been suggested that C6G generates the analgesic activity (8) . Codeine is also N-demethylated into norcodeine (10-15%), via the cytochrome P450 isoenzyme 3A4 (CYP3A4), and norcodeine is further glucuronidated into norcodeine-6-glucuronide (N6G), with a minor proportion being O-demethylated into normorphine (5) .
Codeine is widely prescribed in Norway (1) and is frequently detected in blood samples collected from drivers suspected of driving under the influence of drugs (9) and from autopsy cases, analyzed at the Norwegian Institute of Public Health (NIPH). In forensic toxicology, the codeine to morphine concentration ratio, in blood and urine, is used to evaluate whether codeine has been ingested (10) or if the findings are due to a consumption of other opiates (10) (11) (12) (13) . The interpretation of the codeine to morphine concentration ratios in autopsy cases are based on knowledge from the metabolism of codeine to morphine in living subjects.
Kronstrand et al. showed a maximum codeine to morphine concentration ratio in blood from living subjects of 32 (ranging 24-49), after the ingestion of 100 mg codeine, with a ratio of 2 after 23 h (14). Quiding et al. reported that in plasma the morphine concentration is 2 -3% of the codeine concentration, when measured simultaneously (15) .
Postmortem changes will affect drug concentrations, due to the redistribution of the drug along a concentration gradient, from tissues like lungs, heart or liver into the blood, and also due to the formation and breakdown of drugs (16) . In the case of morphine, it has been shown that morphine glucuronides may be hydrolyzed postmortem, releasing free morphine. As a consequence, the postmortem concentrations of morphine are not necessarily representative of the perimortem blood concentration levels (17, 18) . It is still unclear if the previous also holds true for codeine and C6G.
Changes in the concentration ratios of codeine to morphine may also take place after blood samples have been collected, due to in vitro changes in the vial. It is not known if codeine and morphine glucuronides are subject to the same extent of cleavage in authentic samples from living persons compared with autopsy cases.
From our routine cases, we have experienced that the interpretation of codeine and morphine concentrations is more difficult in autopsy cases compared with samples from living persons. In several autopsy cases, we have found high morphine concentrations, and thus low codeine to morphine ratios indicating additional ingestion of morphine, although other information in these cases have indicated ingestion of codeine alone. This is not a challenge in the samples from living persons, but to our knowledge, no studies have investigated these differences. The aim of this study was therefore to investigate if changes could occur in vitro, after sampling, in the concentrations of six codeine metabolites, using samples collected both from living subjects and from forensic autopsy cases, after being incubated at a high temperature to create a condition that may facilitate the cleavage of the glucuronides and allowing time for in vitro changes to occur in the metabolite concentrations. Our purpose is to investigate whether the cleavage of morphine glucuronides is more extensive than the cleavage of codeine glucuronides, thus changing the codeine to morphine ratio in the samples.
Experimental

Samples
All samples utilized, in the presented study, are authentic whole blood samples, collected over a 6-year period, and analyzed at the NIPH. The institute receives venous whole blood samples from living subjects suspected of being under the influence of drugs. Postmortem whole blood samples are received from forensic autopsies, sampled from the femoral vein. All samples are routinely screened for a standard selection of drugs of abuse, and all of the positive results are confirmed by a second analytical method.
Blood from living subjects were collected into 5 mL Vacutainer w tubes, containing 20 mg sodium fluoride (NaF; a preservative) and 143 IU of heparin (BD Vacutainer Systems, Belliver Industrial Estate, Plymouth, UK). Postmortem blood samples from autopsies were collected into 20 mL Steriline w tubes (Bibby Sterilin, Staffordshire, UK), containing 0.3 mL 67% (w/v) potassium fluoride (KF) solution (also a preservative).
Eight samples from living subjects and nine samples from autopsy cases, containing codeine and morphine, were selected, for this study, using a specific set of criteria. In order to investigate if different changes might take place at varying concentration levels, samples containing both moderate and high codeine concentrations were used.
Criteria for selecting the samples To be able to investigate codeine cases specifically, only cases containing low morphine concentrations were included. Samples containing both codeine and morphine, in whole blood, were included by applying the following criteria:
Cases containing 'high' codeine concentrations:
Four postmortem samples were selected with codeine .1.0 mg/L and morphine ,0.1 mg/L. Among the living cases, however, only three samples were found in the database containing codeine .1.0 mg/L and low morphine concentrations.
Cases containing 'moderate' codeine concentrations:
Five samples were selected from each category (living and postmortem) with codeine between 0.2 and 0.6 mg/L and morphine ,0.03 mg/L.
All cases containing the heroin metabolite 6-acetylmorphine (6-AM), in blood or urine, were excluded.
Methods
After the initial routine analyses at the NIPH, all of the samples were stored in a freezer at 2208C. The samples chosen for this study were thawed and allocated into two vials; one sample for analysis the following day, and the other for incubation at 378C for 14 days before reanalysis. Analyses for codeine, morphine, M3G, M6G, C6G, norcodeine and normorphine were performed by using a previously published LC-MS-MS method (19) .
Limits Norcodeine and normorphine had a day-to-day RSD between 6 and 23% (norcodeine: 0.0020/0.020/0.20 mg/L; normorphine: 0.0019/0.019/0.19 mg/L). Intraday relative standard deviations, for all of the compounds, were ,12%, at the same concentration levels. Changes in concentrations, after reanalysis, between +20% are considered to be within the normal analytical variation.
Results
Samples from living subjects
The concentrations detected for codeine and its metabolites are presented in Table I . The changes, given in percentage, from the initial concentrations are also shown. Five samples, with codeine in the range of 0.2 -0.6 mg/L, were analyzed, but for samples containing codeine .1.0 mg/L, with low morphine concentrations, only three samples were found.
Only minimal changes were observed for the codeine concentrations after incubation, from a reduction of 5% to an increase of 13% (mean 5%), which is within the range considered to be caused by analytical variation. For morphine, the concentrations increased between 33 and 87% (mean 51%).
For most of the metabolites, no changes in the concentrations were found after incubation (the results were within +20%, which is within the analytical variation), but an increase in normorphine concentrations were seen in all the cases, from 43 to 116% (mean 78%).
Autopsy samples
The concentrations of codeine and its metabolites are presented in Table II . The changes from the initial concentrations, given in percentage, are also shown.
Table I
The concentrations of codeine and codeine metabolites (mg/L) in samples collected from living subjects on Day 1 and after 14 days of incubation, and the change in concentrations given in percentage The changes in concentrations of codeine after incubation ranged from a reduction of 26% to an increase of 50% (mean 19%). For morphine, the concentrations increased between 10 and 200% (mean 85%).
As observed for the living cases, an increase in normorphine concentrations were also seen in all the autopsy cases, from 28 to 116% (mean 57%).
Changes in codeine to morphine concentration ratios The changes in codeine to morphine concentration ratios after 14 days of incubation are shown in Table III , and a reduction in the ratios were seen for all the samples. The mean reduction in the codeine to morphine concentration ratio after incubation for samples from living subjects was 33% (ranging 22 -50%). The mean reduction in the codeine to morphine concentration ratio in the postmortem samples after incubation was 37% (ranging 13 -54%).
Discussion
The study reveals that the codeine to morphine concentration ratios in blood were reduced after incubation, both in samples collected from living subjects and from autopsies. Morphine and normorphine concentrations increased in both categories. The codeine and C6G concentrations were not altered after incubation. Why changes are seen in the concentrations of morphine and its metabolites, and not codeine and its metabolites, is not known, but this fact is very important to be aware of during interpretation of such cases.
The interindividual variation in the codeine to morphine ratios may be due to interindividual variation in vivo, such as differences in the genotype encoding enzymes metabolizing codeine to morphine, and also different time periods between last codeine ingestion and sampling. Frost et al. performed CYP2D6 genotyping in samples from deceased subjects to investigate if genotyping could be applied to predict the morphine to codeine concentration ratios in postmortem toxicological specimens (20) . He concluded that investigations on codeine-related deaths should include quantification of morphine and morphine metabolites, together with a detailed case history, in order to achieve a comprehensive interpretation of postmortem codeine findings, and that CYP2D6 genotyping may be of interest in cases with unexpectedly high or low ratios. In our study, the samples were not genotyped, as it was not considered relevant. The lack of genotyping would, according to the previous conclusion, only influence the interpretation of the concentrations measured on Day 1, and not influence the changes observed in the vials in vitro nor during incubation. Previously published data indicate that codeine and morphine may exhibit postmortem redistribution, but the results are inconsistent, particularly for morphine (16, (21) (22) (23) (24) (25) (26) . The increased morphine concentrations observed in our study are likely due to the cleavage of morphine glucuronides. A slightly larger reduction was seen for M3G concentrations, compared with M6G concentrations, but due to the small number of cases investigated, this could be only within the range of analytical variation. Romberg and Lee have however compared the hydrolysis rates of M3G with M6G, and showed that the enzymatic hydrolysis rate of M6G constituted 25% of that of M3G (27) . They found that the hydrolysis of M3G and M6G was complete within 24 h. Two other studies have investigated the stability of the morphine glucuronides in vitro, under different storage conditions (17, 18) . Carroll et al. concluded that hydrolysis, during specimen storage, can generate free morphine from M3G; possibly resulting in erroneous conclusions when certifying narcotic deaths (18). Skopp et al. found that morphine and its glucuronides, in both blood and plasma, are stable at 48C for the observation period; however, in postmortem blood, the analytes are stable only when stored at 2208C. Thus, it is likely that M3G is more prone to hydrolysis than M6G, but the reason for this fact remains unknown. Because the concentrations of M3G are several times higher than both that of M6G and morphine, the contribution of morphine from M3G might be expected to result in a significant increase in the morphine concentration, but it is however important to have in mind that the higher concentrations of the morphine-glucuronides are due to a lower volume of distribution compared with morphine.
Our study reveals that both codeine and C6G concentrations remain stable during incubation, and this is an important finding. Using incubation to study changes taking place after sampling constitutes a worst case scenario. In forensic toxicology cases, it is important to be able to reveal what might happen in such samples, since the conclusion might have serious consequences for the sample donor. The reason for codeine and C6G appearing more stable than morphine and morphine glucuronides is unknown, but one explanation may be an inherent stability in the chemical structure of the substance. No previous studies seem to have investigated this hypothesis. For M6G, C6G and norcodeine, opposing changes in the concentrations were observed, in both samples from living subjects and from autopsy cases; however, the changes were within the range of normal analytical variation of +20%.
No differences in the codeine concentrations were observed between samples with 'high' and 'moderate' codeine concentrations, after incubation. But due to the limited number of cases included, a conclusion cannot be drawn as to whether such differences may or may not take place. Because the changes observed appear to be due to in vitro changes in the morphine concentrations, and not in the codeine concentrations, larger differences in the codeine to morphine concentration ratio might have been expected in cases with higher original morphine concentrations. It is well known that due to genetic polymorphism on the CYP2D6 gene, the amount of morphine produced from codeine varies. About 1 -3% of Caucasians have an allele duplication resulting in 'ultrarapid metabolizers' (4), and larger proportion of the ingested codeine can be metabolized into morphine (5) . In such cases, the codeine to morphine ratio might thus be lower than expected as a consequence of ingestion of only codeine, and there might be a risk that intake of morphine and/ or heroin is suspected.
An increase in the normorphine concentrations are seen for all the samples from both living and autopsy cases. We have not found any literature that can explain this increase. This finding does however reveal that this metabolite might not be a good indicator for the morphine concentrations at the time of sampling from living persons, or at the time of death. The postmortem changes in normorphine concentrations are also unknown.
The samples included in this study were selected using a specific set of criteria, with the intent of making it more likely that the concentrations of codeine and morphine detected were due to the ingestion of codeine alone. The ingestion of morphine or heroin cannot be ruled out completely, but the criteria, including low morphine and high codeine concentrations, should make it less likely. Cases revealing 6-AM, in blood or urine, were excluded.
Finding cases suitable for this study was a challenge. Although codeine is frequently used in Norway, ingestion of codeine only, is very rare in these types of cases, and the sample size is therefore small. Samples from living persons or from autopsies are however obligated to study such changes, since processes that have taken place after death lead the different level of glucuronides and matrix effects might influence the drug concentrations in vitro to a different extent in samples from different persons. Spiked samples can thus not be used to examine this. Due to the low number of cases, statistical analyses have not been performed. The aim of the study was, however, to investigate if changes could occur in vitro after sampling; and even with our low number of cases, we were able to show such changes to take place. It is therefore likely that even greater changes would have been observed if the sample size was larger.
For the overall cases from the living persons and the autopsy cases, we did not see major differences between the groups. Looking at the range for the different parameters that we have investigated, we found large changes in the autopsy group. Our impression prior to this study was that the changes in the codeine to morphine ratio were most pronounced in the autopsy cases, and the findings from this study could only to some extent confirm this assumption. One of the autopsy cases did however show a 200% increase in the morphine concentration after incubation, and if such an increase is found in cases where a larger amount of morphine has been formed from codeine, this might lead to difficulties regarding interpretation. The changes observed in routine autopsy cases received at our lab might also be due to changes that have taken place in the body before sampling, and further studies are needed to investigate this.
Tolliver et al. examined the relationship between ante-and postmortem morphine and codeine concentrations in whole blood (23) . Their study indicated that several factors, such as metabolism and postmortem interval, may affect the postmortem drug concentrations in an unpredictable manner. The majority of the cases, where postmortem concentrations exceeded that of the antemortem concentrations, could not simply be explained by metabolism alone, but, in addition, by the postmortem release of drugs. The previous may be further exacerbated by the increase in postmortem intervals and by the sampling of a pooled mixture of blood. In our study, the influence of postmortem redistribution and the metabolism of codeine were negligible as it had already taken place before sampling. The results reveal that changes also may take place after sampling, during transportation to the analysis laboratory, under freezing and thawing, and before analysis. Such in vitro changes, occurring in the vials, must be caused by formation from other metabolites or by degradation. Incubation is not a realistic scenario for the handling of such routine samples, but this has been used to illustrate what might happen with the different codeine metabolites in vitro. It is important to emphasize that this study has not investigated the stability of the drug concentrations during storage. The concentration ratios selected in this study do not represent cases where there have been difficulties with the interpretation of the findings, with respect to codeine ingestion. But the knowledge from this small study provides important information that can be applied on other cases, where such a conclusion is challenging.
Conclusion
The codeine to morphine concentration ratio in blood depends on interindividual variation in the metabolism of codeine to morphine, on postmortem redistribution, and on in vitro changes occurring after sampling. In this study, the changes that may take place in vitro, following sampling have been investigated after incubation, using a worst case scenario to be able to illustrate what might take place. The increase in the morphine concentrations, followed by the reduction in codeine to morphine ratios, is seen both in samples collected from autopsies and from living samples. Increased concentrations of normorphine were also found, while minor changes were seen for the other metabolites.
The number of samples studied is small, and compared with what might be seen in such cases, we have only included samples with low morphine concentrations. Larger changes in the codeine to morphine ratios are therefore likely to be found, especially in cases from 'ultrarapid metabolizer' at the CYP2D6, where higher morphine concentrations are present, and changes in the morphine concentration to a larger extent will contribute to lowering the codeine to morphine ratio. This must be kept in mind when interpreting opiate cases. The mechanisms underlying the differences we have found for codeine and morphine are still unknown, and also if codeine and morphine have different properties regarding postmortem changes. Even though this is an in vitro study, the changes observed is likely to be part of the postmortem redistribution process, and are changes that might take place in the body, after death. Further investigations are warranted.
